Patrys Limited · ASX:PAB
Patrys — Investor Presentation (September 2022)
25 slides from Patrys's investor presentation, Sep 1, 2022
Slide 1: Investor Presentation September 2022
For personal use only Investor Presentation September 2022
Slide 2: Safe harbour statement
Safe harbour statement For personal use only The following material is for general information purposes only and is not to be relied upon for the making of an investment decision. Any investment in Patrys Limited ACN 123 055 363 (Patrys) is subject to investment risk including the possibility of los
Slide 3: Investment summary
Investment summary For personal use only Patrys’ deoxymab technology platform provides new ways for using antibodies to treat cancer: Block repair of damaged DNA Cross the blood brain barrier Can be used alone or in combination with other therapies Deoxymab antibodies can be used as targeting agents
Slide 4: Company snapshot
Company snapshot For personal use only Shares 2.1B Market cap¹ A$55M Cash² A$9.8M HQ Melbourne Michael Stork (Interim Chair) James Campbell (CEO & MD) Board Pamela Klein (NED) Suzy Jones (NED) Stefan Ross (NED) Price¹ $0.027 Dr Dax Marcus Calder – 11.2% Substantial 12 mth high - low $0.047 - $0.019
Slide 5: Board of Directors
Board of Directors For personal use only Mike Stork (Interim Chair) Dr Pamela M. Klein Managing Director of Stork Holdings Ltd, Former VP, Development at Genentech active in Canadian technology start-up sector Board member of Argenx (Euronext & Nasdaq: ARGX) Director of multiple leading Canadian For
Slide 6: Overview Technology
For personal use only Overview Technology
Slide 7: First anticancer therapeutic Ab targeting DDR
First anticancer therapeutic Ab targeting DDR For personal use only Deoxymabs bind to DNA and have a unique combination of properties: Cancer seeking: tumours release DNA which attracts deoxymabs Cell penetrating: able to get into cells and the cell nucleus Block DNA damage repair (DDR): stops cance
Slide 8: Deoxymabs: multiple therapeutic approaches
Deoxymabs: multiple therapeutic approaches For personal use only Single Agent Combination Therapies Targeted Therapies Many cancers have pre-existing defects Radiation therapy and many chemo Antibody drug conjugates to target in their DNA damage repair (DDR) drugs work by causing damage to DNA paylo
Slide 9: Results Deoxymab
For personal use only Results Deoxymab
Slide 10: Improves survival in primary brain cancer
Improves survival in primary brain cancer For personal use only Mice with human GBM Glioblastoma (GBM) is the most common primary brain cancer (23,000 new cases in the US pa) GBM is highly aggressive with few effective treatment options (5- year survival rate = 5.6%) Standard of Care for GBM is surg
Slide 11: Improves effectiveness of radiation
Improves effectiveness of radiation For personal use only Radiation is the standard of care for GBM patients Mice with high-grade glioma Dose of radiation is limited by its side-effects Combining with PAT-DX1 reduces the ability of cancer cells to repair DNA damage caused by radiation ~25% improveme
Slide 12: Effective against brain metastases
Effective against brain metastases For personal use only ~ 200,000 new cases of brain metastases (secondary brain cancer) Breast Cancer Brain Metastases in the US each year The primary cancers that most often spread to the brain are cancers of the lung, breast, skin, colon, kidney and thyroid Median
Slide 13: PAT-DX1 potential use in pancreatic cancer
PAT-DX1 potential use in pancreatic cancer For personal use only Pancreatic cancer is one of the most common and aggressive Pancreatic Cancer Model cancer types, with a 5-year survival rate of 2–9%¹ Globally, 460,000 new cases and 432,000 deaths in 2018 Limited treatment options Second leading cause
Slide 14: PAT-DX3 can target cancer drugs to tumours
PAT-DX3 can target cancer drugs to tumours For personal use only Antibody drug conjugates (ADCs) provide additional clinical benefits to antibodies alone Breast Cancer Model Proof of principle study with PAT-DX3 conjugated to MMAE (toxic anti-cancer drug used in approved ADCs) Clear tumour-targeting
Slide 15: Recent Developments
For personal use only Recent Developments
Slide 16: Cure Brain Cancer Foundation Clinical Accelerator
Cure Brain Cancer Foundation Clinical Accelerator For personal use only $250k in non-dilutive funding from inaugural Clinical Accelerator from Cure Brain Cancer Foundation Additional deoxymab preclinical research at The Telethon Kids Institute - led by Professor Terrance Johns International panel se
Slide 17: PAT-DX1 inhibits formation of NETs
PAT-DX1 inhibits formation of NETs For personal use only Peer-reviewed publication reported that PAT-DX1 suppresses the formation of neutrophil extracellular traps (NETs) NETs have been implicated in progression and metastasis in some cancers Offers mechanistic rationale to the previously-described
Slide 18: Ahead Looking
For personal use only Ahead Looking
Slide 19: PAT-DX1 clinical trial preparation for H2 2023
PAT-DX1 clinical trial preparation for H2 2023 For personal use only Cell line selected in 2021 Engineering run successfully completed in July 2022 Non-GLP toxicology in rodents and NHPs clear report GLP toxicology commencing Q4 CY2022 Australian phase 1 dose escalation study in solid tumours planne
Slide 20: PAT-DX3 development path
PAT-DX3 development path For personal use only PAT-DX3 is differentiated from, and complementary to PAT- DX1 Different pharmacokinetic profile Crosses the blood brain barrier in animal models of brain cancer Efficacy in animal models Potential for use as a tumour targeting agent for ADCs (more conju
Slide 21: Development timeline
Development timeline For personal use only 3Q 4Q 1Q 2Q 3Q 4Q 1Q Production GMP production and formulation PAT-DX1 Pre-clinical GLP toxicology Prepare & file Clinical Phase 1 Aust-HREA (IND) Pre-production Master Cell Bank PAT-DX3 Production Downstream development Engineering run GLP toxicology Pre-c
Slide 22: Landscape Commercial
For personal use only Landscape Commercial
Slide 23: Biologics typically transact earlier and at higher valuations
Biologics typically transact earlier and at higher valuations than small molecules For personal use only The value of Patrys’ novel therapy is underpinned by potential for multiple applications to achieve better patient outcomes Source: GlobalData 1. Small molecules and biologics transactions betwee
Slide 24: Relevant recent pre-clinical transactions
Relevant recent pre-clinical transactions For personal use only 24
Slide 25: Contact
Contact For personal use only Dr. James Campbell CEO and MD +61 3 9670 3273 info@patrys.com patrys.com Patrys Limited (ASX:PAB)